EMD-68255

Single-particle
3.2 Å
EMD-68255
3D View Gallery
Deposition: 09/01/2026
Map released: 28/10/2026
Last modified: 28/10/2026
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-68255

Archive Files (Depositor)

Primary 3D volume (map.gz) Half-map 1 Half-map 2 (map.gz) Experimental metadata (xml) Experimental metadata (cif.gz)

Validation (wwPDB)

Map-only validation report (pdf.gz) Map-22gc summary report (pdf.gz) Map-22gc FULL report (pdf.gz)

EMDB Annotations

EMICSS entry mapping (xml)

EMDB Files

VA raw map (map) VA resolution mask (mrc)

The structure of HER2-m66-trastuzumab

EMD-68255

Single-particle
3.2 Å
EMD-68255
3D View Gallery
Deposition: 09/01/2026
Map released: 28/10/2026
Last modified: 28/10/2026
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: Homo sapiens, Chimeric Dengue virus vector p4(Delta30)-D2-ME, Mus musculus
Sample: HER2-m66-trastuzumab
Fitted models: 22gc

Deposition Authors: Liu C , Ren Y , Luo X, Zhou P, Du X, Wang Q, Han X, Xu Y, Wang P, Zhao D , Yang H
Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III/IV.
Liu C , Ren Y , Luo X, Zhou P, Du X, Wang Q, Han X, Xu Y, Wang P, Zhao D , Yang H
(2026) PLoS One , 21 , e0338127 - e0338127
PUBMED: 41538393
DOI: doi:10.1371/journal.pone.0338127
ISSN: 1932-6203
Grant Support: